康华生物 (300841.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1.2B	1.2B	1.4B	1.6B	1.4B
Cost of Revenue	100.7M	92.8M	83.0M	103.3M	93.1M
Gross Profit	1.1B	1.1B	1.3B	1.5B	1.4B
Operating Expenses
R&D Expense	113.8M	118.4M	132.1M	253.0M	179.9M
SG&A Expense	—	—	—	—	—
General & Admin Expense	123.3M	120.6M	111.3M	106.8M	82.7M
Selling & Marketing Expense	575.9M	557.6M	547.1M	494.3M	428.1M
Other Expenses	—	—	—	—	—
Total Operating Expenses	822.4M	802.3M	792.2M	856.0M	688.0M
Cost and Expenses	923.0M	895.1M	875.2M	959.3M	781.1M
Operating Income (EBIT)	269.5M	259.9M	467.3M	576.6M	685.5M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	269.2M	259.7M	467.0M	574.0M	683.8M
Income Tax Expense	42.7M	39.8M	68.4M	64.8M	85.7M
Bottom Line
Net Income	226.6M	219.9M	398.7M	509.2M	598.1M
Earnings from Cont. Ops	58.2M	219.9M	398.7M	509.2M	598.1M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	226.6M	219.9M	398.7M	509.2M	598.1M
Per Share
Basic EPS	CN¥1.74	CN¥1.69	CN¥3.03	CN¥3.81	CN¥4.47
Diluted EPS	CN¥1.74	CN¥1.69	CN¥3.03	CN¥3.81	CN¥4.46
Revenue Per Share	CN¥9.23	CN¥8.97	CN¥10.88	CN¥11.79	CN¥10.80
Shares
Basic Shares Outstanding	129.9M	129.9M	131.7M	133.7M	133.9M
Diluted Shares Outstanding	129.9M	129.9M	131.7M	133.7M	133.9M
Profitability Metrics
EBITDA	—	348.4M	542.0M	637.9M	725.4M
D&A	—	88.5M	74.7M	61.3M	39.9M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026